225 related articles for article (PubMed ID: 16923559)
1. High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphoma.
Hosing C; Saliba RM; Körbling M; Acholonu S; McMannis J; Anderlini P; Giralt S; De Lima M; Okoroji GJ; Couriel DR; Champlin R; Khouri IF; Donato ML
Leuk Lymphoma; 2006 Jul; 47(7):1290-4. PubMed ID: 16923559
[TBL] [Abstract][Full Text] [Related]
2. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma.
Buckstein R; Imrie K; Spaner D; Potichnyj A; Robinson JB; Nanji S; Pennel N; Reis M; Pinkerton P; Dubé I; Hewitt K; Berinstein NL
Semin Oncol; 1999 Oct; 26(5 Suppl 14):115-22. PubMed ID: 10561026
[TBL] [Abstract][Full Text] [Related]
3. Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma.
Donato ML; Champlin RE; Van Besien KW; Korbling M; Cabanillas F; Anderlini P; Gajewski JG; Lauppe J; Durett A; Andersson B; Giralt S; Khouri I; Hagemeister F; Romaguera JE; Sarris A; McLaughlin P; Younes A; Ippoliti C; Blamble DA; Hester J; Gee A; Rodriguez MA
Leuk Lymphoma; 1999 Oct; 35(3-4):317-24. PubMed ID: 10706456
[TBL] [Abstract][Full Text] [Related]
4. Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma.
Aurlien E; Holte H; Pharo A; Kvaløy S; Jakobsen E; Smeland EB; Kvalheim G
Bone Marrow Transplant; 1998 May; 21(9):873-8. PubMed ID: 9613778
[TBL] [Abstract][Full Text] [Related]
5. In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma.
Voso MT; Pantel G; Weis M; Schmidt P; Martin S; Moos M; Ho AD; Haas R; Hohaus S
Br J Haematol; 2000 Jun; 109(4):729-35. PubMed ID: 10929022
[TBL] [Abstract][Full Text] [Related]
6. [Comparison of the effectiveness of hematopoietic cell mobilization with chemotherapy and filgrastim versus filgrastim alone for autologous transplant in patients with lymphoma.].
Gutiérrez-Aguirre CH; De la Garza-Salazar F; Cantú-Rodríguez O; González-Llano Ó; Jaime-Pérez JC; Mancias-Guerra C; García-Sepúlveda R; Salazar-Riojas R; Gómez-Almaguer D
Gac Med Mex; 2016 Oct; 152(Suppl 2):57-65. PubMed ID: 27792717
[TBL] [Abstract][Full Text] [Related]
7. Dose-Modified Ifosfamide, Epirubicin, and Etoposide is a Safe and Effective Salvage Therapy with High Peripheral Blood Stem Cell Mobilization Capacity for Poorly Mobilized Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma Patients.
Fukunaga A; Hyuga M; Iwasaki M; Nakae Y; Kishimoto W; Maesako Y; Arima N
J Clin Exp Hematop; 2016; 56(1):50-4. PubMed ID: 27334858
[TBL] [Abstract][Full Text] [Related]
8. Mitoxantrone/ifosfamide/etoposide salvage regimen with rituximab for in vivo purging in patients with relapsed lymphoma.
Emmanouilides C; Lill M; Telatar M; Rosenfelt F; Grody W; Territo M; Rosen P
Clin Lymphoma; 2002 Sep; 3(2):111-6. PubMed ID: 12435284
[TBL] [Abstract][Full Text] [Related]
9. Factors determining pbsc mobilization efficiency and nonmobilization following ICE with or without rituximab (R-ICE) salvage therapy for refractory or relapsed lymphoma prior to autologous transplantation.
Xia W; Ma CK; Reid C; Bai L; Wong K; Kerridge I; Ward C; Greenwood M
J Clin Apher; 2014 Dec; 29(6):322-30. PubMed ID: 24944079
[TBL] [Abstract][Full Text] [Related]
10. Rituximab and ifosfamide, mitoxantrone, etoposide (RIME) with Neupogen support for B-cell non-Hodgkin's lymphoma prior to high-dose chemotherapy with autologous haematopoietic transplant.
Joyce RM; Kraser CN; Tetrealt JC; Giallombardo N; McDermott D; Levine J; Umiel T; Regan M; Hurley D; Uhl L; Avigan D
Eur J Haematol Suppl; 2001 Jul; 64():56-62. PubMed ID: 11486404
[TBL] [Abstract][Full Text] [Related]
11. Transplantation potential of peripheral whole blood primed by VACOP-B chemotherapy plus filgrastim (r-metHuG-CSF) in patients with aggressive non-Hodgkin's lumphoma.
Corato A; Ambrosetti A; Rossi B; Vincenzi C; Lambiase A; Perona G; Pizzolo G; de Wynter E; Nadali G
J Hematother Stem Cell Res; 2000 Oct; 9(5):673-82. PubMed ID: 11091491
[TBL] [Abstract][Full Text] [Related]
12. Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients.
Aurlien E; Holte H; Kvaløy S; Jakobsen E; Rusten LS; Kvalheim G
Eur J Haematol Suppl; 2001 Jul; 64():14-20. PubMed ID: 11486395
[TBL] [Abstract][Full Text] [Related]
13. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF.
Engelhardt M; Winkler J; Waller C; Lange W; Mertelsmann R; Henschler R
Bone Marrow Transplant; 1997 Mar; 19(6):529-37. PubMed ID: 9181898
[TBL] [Abstract][Full Text] [Related]
14. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma.
Moskowitz CH; Bertino JR; Glassman JR; Hedrick EE; Hunte S; Coady-Lyons N; Agus DB; Goy A; Jurcic J; Noy A; O'Brien J; Portlock CS; Straus DS; Childs B; Frank R; Yahalom J; Filippa D; Louie D; Nimer SD; Zelenetz AD
J Clin Oncol; 1999 Dec; 17(12):3776-85. PubMed ID: 10577849
[TBL] [Abstract][Full Text] [Related]
15. Mobilisation of peripheral blood stem cells with IVE and G-CSF improves CD34+ cell yields and engraftment in patients with non-Hodgkin's lymphomas and Hodgkin's disease.
McQuaker I; Haynes A; Stainer C; Byrne J; Russell N
Bone Marrow Transplant; 1999 Oct; 24(7):715-22. PubMed ID: 10516673
[TBL] [Abstract][Full Text] [Related]
16. [Effect of growth factor on the phenotype of subpopulations and on the kinetics of CD34+ cells in the peripheral blood and in grafts of peripheral stem cells in patients with non-Hodgkin's lymphoma indicated for autologous peripheral blood stem cell transplantation].
Klabusay M; Lysák D; Hrabcáková V; Navrátil M; Coupek P; Mayer J
Cas Lek Cesk; 2008; 147(6):319-24. PubMed ID: 18724529
[TBL] [Abstract][Full Text] [Related]
17. Autografting followed by nonmyeloablative immunosuppressive chemotherapy and allogeneic peripheral-blood hematopoietic stem-cell transplantation as treatment of resistant Hodgkin's disease and non-Hodgkin's lymphoma.
Carella AM; Cavaliere M; Lerma E; Ferrara R; Tedeschi L; Romanelli A; Vinci M; Pinotti G; Lambelet P; Loni C; Verdiani S; De Stefano F; Valbonesi M; Corsetti MT
J Clin Oncol; 2000 Dec; 18(23):3918-24. PubMed ID: 11099321
[TBL] [Abstract][Full Text] [Related]
18. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
Nademanee A; Sniecinski I; Schmidt GM; Dagis AC; O'Donnell MR; Snyder DS; Parker PM; Stein AS; Smith EP; Molina A
J Clin Oncol; 1994 Oct; 12(10):2176-86. PubMed ID: 7523609
[TBL] [Abstract][Full Text] [Related]
19. Phase II study of a single pegfilgrastim injection as an adjunct to chemotherapy to mobilize stem cells into the peripheral blood of pretreated lymphoma patients.
Isidori A; Tani M; Bonifazi F; Zinzani P; Curti A; Motta MR; Rizzi S; Giudice V; Farese O; Rovito M; Alinari L; Conte R; Baccarani M; Lemoli RM
Haematologica; 2005 Feb; 90(2):225-31. PubMed ID: 15710576
[TBL] [Abstract][Full Text] [Related]
20. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.
Russell N; Mesters R; Schubert J; Boogaerts M; Johnsen HE; Canizo CD; Baker N; Barker P; Skacel T; Schmitz N
Haematologica; 2008 Mar; 93(3):405-12. PubMed ID: 18268285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]